New Research Paper Addressing Concerns about Generic ADHD Medication / Health Canada Up-dates on the Issue

Since 2010 CADDAC has shared our concerns about the direct substitution of methylphenidate ER-C, a generic medication, for OROS® methylphenidate (Concerta) with Health Canada. This was done through documentation, caregiver and patient survey results and several face to face meetings. A Canadian research paper reviewing data on this issue, was recently published in the Clinical…

ADHD in Education Awareness/Advocacy Campaign

2017/2018 ADHD in Education Awareness/Advocacy Campaign To better advocate for students with ADHD we need to hear from you! Download, share and post our Education Campaign Flyer  Access our Education Survey Share your Canadian Education Experiences advocacy@caddac.ca  This October, during ADHD Awareness Month, CADDAC is launching our “ADHD in Education Awareness/Advocacy Campaign” to draw greater…

Far Fewer Mental Health Medications are Recommended for Listing on Government Drug Plans When Compared to Non-mental Health Medications?

This very enlightening study questions how genuine our government’s call is for improved mental health treatment. While medication is only one treatment option, for many impacted by a mental health disorder, the right medication treatment can be life changing. This study published by the Canadian Health Policy Institute (CHPI), compares decisions on access to medications…

Recent Meeting with Health Canada Regarding Generic Concerta

On October the 31st CADDAC and CADDRA, as well as other stake holders, met with Health Canada to present our activities over the past six years and express our continued concerns in regards to the bioequivalency, or more accurately the lack of therapeutic equivalence, of the generic forms of the brand name ADHD medication Concerta. …